Patent Theme
Nucleic Acid-Based Therapies
Therapeutic strategies employing nucleic acids (DNA, RNA, oligonucleotides) to modulate gene expression, deliver genetic material, or interfere with disease-causing pathways. Includes gene therapy using viral vectors.
16,190 US filings from 4,472 companies since 2023 · 2023: 3,688 · 2024: 5,206 · 2025: 5,220 · 2026 YTD: 2,076
Pharmaceutical PreparationsTherapeutic Activity (Pharma)
Top companies
Ranked by filings in this theme since 2023. 2026 is partial.
| # | Company | Since 2023 | 2023 | 2024 | 2025 | 2026 YTD | YoY |
|---|
| 1 | The Regents of the University of California | 331 | 93 | 106 | 92 | 40 | -13.2% |
| 2 | UNIVERSITY OF MASSACHUSETTS | 235 | 57 | 69 | 67 | 42 | -2.9% |
| 3 | Alnylam Pharmaceuticals, Inc. | 223 | 52 | 80 | 69 | 22 | -13.8% |
| 4 | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 222 | 49 | 68 | 77 | 28 | +13.2% |
| 5 | President and Fellows of Harvard College | 222 | 57 | 61 | 76 | 28 | +24.6% |
| 6 | The Broad Institute, Inc. | 183 | 39 | 48 | 73 | 23 | +52.1% |
| 7 | ModernaTX, Inc. | 181 | 41 | 60 | 60 | 20 | 0.0% |
| 8 | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 154 | 44 | 46 | 44 | 20 | -4.3% |
| 9 | Ionis Pharmaceuticals, Inc. | 131 | 30 | 49 | 40 | 12 | -18.4% |
| 10 | Wyvern Pharmaceuticals Inc. | 127 | · | 2 | 83 | 42 | +4050.0% |
| 11 | Gilead Sciences, Inc. | 113 | 33 | 42 | 33 | 5 | -21.4% |
| 12 | The Board of Trustees of the Leland Stanford Junior University | 102 | 19 | 36 | 30 | 17 | -16.7% |
| 13 | TRANSLATE BIO, INC. | 100 | 23 | 32 | 31 | 14 | -3.1% |
| 14 | Duke University | 97 | 21 | 44 | 20 | 12 | -54.5% |
| 15 | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 96 | 20 | 22 | 36 | 18 | +63.6% |
| 16 | CureVac SE | 91 | 16 | 31 | 32 | 12 | +3.2% |
| 17 | Hoffmann-La Roche Inc. | 88 | 24 | 24 | 29 | 11 | +20.8% |
| 18 | The Board of Regents of The University of Texas System | 85 | 14 | 44 | 18 | 9 | -59.1% |
| 19 | Regeneron Pharmaceuticals, Inc. | 84 | 8 | 19 | 40 | 17 | +110.5% |
| 20 | BioNTech SE | 79 | 13 | 26 | 31 | 9 | +19.2% |
| 21 | The Johns Hopkins University | 78 | 24 | 19 | 24 | 11 | +26.3% |
| 22 | GlaxoSmithKline Biologicals SA | 76 | 41 | 23 | 11 | 1 | -52.2% |
| 23 | Yale University | 76 | 23 | 21 | 25 | 7 | +19.0% |
| 24 | Flagship Pioneering Innovations VI, LLC | 75 | 16 | 31 | 18 | 10 | -41.9% |
| 25 | Arrowhead Pharmaceuticals, Inc. | 74 | 16 | 13 | 28 | 17 | +115.4% |